A Phase 3 Substudy to Evaluate Executive Function in Adults With PKU Who Are Participating in the Phase 3 Study, 165-302

Key facts

Sponsor

BioMarin Pharmaceutical

Principal Investigator

Debra Lounsbury

Principal Scientist/Medical Monitor

Intervention

Administration of CANTAB and Subject Global Assessment(other)

Enrollment

9 enrolled

Eligibility

18-70 years · All sexes

Timeline

2015 – 2017

Study locations (4)

• University of Kentucky Medical Center, Lexington, Kentucky, United States
• University of Nebraska Medical Center, Omaha, Nebraska, United States
• University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
• Oregon Health and Science University, Portland, Oregon, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Classic phenylketonuria

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07241234
  A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria
  Agios Pharmaceuticals, Inc.
• RECRUITINGNANCT07526909
  Effect of Different Meal Types Given Before Exercise on Plasma Amino Acid Levels and Metabolic Control Parameters in Classical Phenylketonuria Patients Undergoing Aerobic and Resistance Exercises
  Hacettepe University
• ACTIVE NOT RECRUITINGPHASE4NCT06780332
  Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Palynziq
  BioMarin Pharmaceutical
• RECRUITINGNANCT01659749
  Educational, Social Support, and Nutritional Interventions and Their Cumulative Effect on Pregnancy Outcomes and Quality of Life in Teen and Adult Women With Phenylketonuria
  Emory University

See all trials for Classic phenylketonuria →